91. Dent J. Microscopic esophageal mucosal injury in non-erosive reflux disease. Clin Gastroenterol Hepatol 2007; 5:4–16.
92. Castell JO, Gideon RM. Esophageal Manometry. En Castell DO, Ed, The Esophagus. Philadelfia: Lippincot 2006:101.
93. Pose AC, Reyes L, Saona G, Umpierre V. Manometría esofágica en pacientes con disfagia, reflujo gastroesofágico y dolor torácico no cardíaco. Utilidad diagnóstica. Rev Med Urug 2009;25:34-44
94. Tutuian R, Castell DO. Classification of the esophageal function defect in patients with manometric ineffective esophageal motility: studies using combined impedance-manometry. Gastroenterology 2004; 2:230–9.
95. Camargo MC, Yepez MC, Cerón C, Guerrero N, Bravo LE, Correa P, et al. Age at acquisition of Helicobacter pylori infection: Comparison of two areas with contrasting risk of gastric cancer. Helicobacter 2006 Jun; 9(3):262-70.
96. Vakil N, Van Zanten SV, Kahrilas P, et al. The Montreal definition and classification of gastroesophageal reflux disease: a global evidence based consensus. Am J Gastroenterol 2006;101:1900–20.
97. Corley DA, Kubo A. Body mass index and gastroesophageal reflux disease: a systematic review and meta-analysis. Am J Gastroenterol 2006; 108:2619–28.
98. Raghunath A, Hungin AP,Woolf D, et al. Prevalence of Helicobacter pylori in patients with gastro-esophageal reflux disease: a systematic review. BMJ 2003; 326:737–40.
99. Labenz J, Nocon M, Lind T, et al. Prospective follow-up from the ProGERD study suggests that GERD is not a categorical disease. Am J Gastroenterol 2006; 101:2457–62.
100. Wo JM, Mendez C, Harrell S, et al. Clinical impact of upper endoscopy in the management of patients with gastroesophageal reflux disease. Am J Gastroenterol 2004;99:2311–6.
101. Barlow WJ, Orlando RC. The pathogenesis of heartburn in non-erosive disease: a unifying hypothesis. Gastroenterol 2005; 128:771–8..
102. Mehendiratta V, DiMarino V, Cohen S. Clinical Utility of Selective Esophageal Manometry in a Tertiary Care Setting. Dig Dis Sci (2009) 54:1481–1486
103. Prakash C, Clouse RE. Value of extended recording time with wireless pH monitoring in evaluating gastroesophageal reflux disease. Clin Gastroenterol Hepatol 2005; 3:329–34.
104. Bredenoord AJ, Tutuian R, Smout AJPM, Castell DO. Technology review: esophageal impedance monitoring. Am J Gastroenterol 2007; 102:187–94
105. Tutuian R, Castell DO. Classification of the esophageal function defect in patients with manometric ineffective esophageal motility: studies using combined impedance-manometry. Gastroenterology 2004; 2:230–9.
106. Numans ME, Lau J, deWit NJ, et al. Short-term treatment with PPIs as a test for gastroesophageal reflux disease: a meta-analysis of diagnostic test characteristics. Ann Intern Med 2004; 140:518–27.
107. Anido VM, Martínez R, Díaz-Canel O, García-Menocal JL, Pernía L, Díaz Z. Enfermedad por reflujo gastroesofágico: factores de motilidad. Endoscopia 2008; 20(2):120-128.
108. Declaración de Helsinki de la Asociación Médica Mundial. Principios éticos para las investigaciones médicas en seres humanos. Adoptada por la 18a Asamblea Médica Mundial Helsinki, Finlandia, Junio 1964 y enmendada por la 29a Asamblea Médica Mundial Tokio, Japón, Octubre 1975; 35a Asamblea Médica Mundial Venecia, Italia, Octubre 1983, 41a Asamblea Médica Mundial Hong Kong, Septiembre 1989, 48a Asamblea General Somerset West, Sudáfrica, Octubre 1996 y la 52a Asamblea General Edimburgo, Escocia, Octubre 2000.
109. Moraes-Filho JPP. Gastroesophageal reflux disease: prevalence and management in Brazil. Best Pract Res Clin Gastroenterol 2004; 18:23–26
110. Uscanga L, Nogueira-de-Rojas JR, Gallardo E, et al. Gastroesophageal reflux disease. Gastroenterology mexican association consensus. Mexican group for the gerd study. Rev Gastroenterol Mex 2002; 67:216-23.
111. Chen M, Xiong L, Chen H, et al. Prevalence, risk factors and impact of gatroesophageal reflux disease symptoms: A population based study in South China. Scand J Gastroenterol 2005; 40:750–67.
112. Peitza U., Viethb M., Malfertheinera P. Reflujo GE y Helicobacter Pylori: Participación del cardias. Digestive Diseases 2004;22:120-125
113. Anido V, Martínez R et al. Motilidad esofágica en pacientes geriátricos con disfagia. AMECA Diciembre 2004;Vol.6 (2)
114. Guimarães EV, Guerra PV, Penna FJ. Management of gastroesophageal reflux disease and erosive esophagitis in pediatric patients: focus on delayed-release esomeprazole. Ther Clin Risk Manag. 2010 Oct; 21(6):531-7.
115. Anido VM, Martínez R, Díaz-Canel O, García-Menocal JL, García E, Díaz Z. Manometría Esofágica en pacientes difíciles. ¿Contraindicaciones? Revista Habanera de Ciencias Médicas. 2007 Oct-Dic;Vol 6(4)
116. Fisichella PM, Patti MG. Gastroesophageal Reflux Disease. En. http://www.emedicine.com/med/topic857.htm, bajado 5/08/08.
117. Sanz de Villalobos E, Boixeda de Miquel D. Helicobacter pylori y enfermedad por reflujo gastro-esofágico Anales Navarra.2000; Vol 21supl 2.
118. Cheng EH, Bermanski P, Silversmith M, Valenstein P, Kawanishi H. Prevalence of Campylobacter pylori in esophagitis, gastritis and duodenal disease. Arch Intern Med 1989; 149:1373-1375.
119. Francoual S, Lamy PH, Le Quintrec Y, Luboinski J, Petit JC. Helicobacter pylori: Has it part in the lesion of the gastroesophageal reflux. J Infect Dis 1990; 162:1414-1415.
120. O'Connor HJ, Cunnane K. Helicobacter pylori and gastro-oesophageal reflux disease. A prospective study. Ir J Med Sci1994; 163: 369.
121. Wittmann T, Fehér A, Rosztóczy A, Jármay K, Lénart Zs. Does the Helicobacter pylori infection aggravate gastroesophageal reflux disease (abstract). Gut 1995, 37:A224.
122. Boixeda D, Gisbert JP, Cantón R, Álvarez Baleriola I, Gil Grande LA, Martín de Argila C. ¿Por Helicobacter pylori y la esofatitis péptica?. Med Clin (Barc) 1995; 105:774-777.
123. Csendes A, Smok G, Cerda G, Burdiles P, Mazza D, Csendes P. Prevalence of Helicobacter pylori infection in 190 control subjects and in 236 patients with gastroesophaheal reflux, erosive esophagitis or Barrettís esophagus. Dis Esophagus 1997; 10:3842.
124. Gonzalez-Carvajal M. Aspectos epidemiológicos de mayor relieve de la infección por Helicobacter pylori. En: Gonzalez-Carvajal M. Helicobacter pylori ¿el tercer dogma?. Edit Autores Productores Asociados, SL. Madrid,2003
125. Herbella FA, Patti MG. Gastroesophageal reflux disease: From pathophysiology to treatment. World J Gastroenterol 2010 August 14; 16(30):3745-3749
126. Moraes-Filho JP, Navarro-Rodriguez T, Barbuti R, Eisig J, Chinzon D, Bernardo W; Brazilian Gerd Consensus Group. Guidelines for the diagnosis and management of gastroesophageal reflux disease: an evidence-based consensus. Arq Gastroenterol. 2010 Mar; 47(1):99-115.
127. Grande M, Cadeddu F, Villa M, Attinà GM, Muzi MG, Nigro C, Rulli F, Farinon AM. Helicobacter pylori and gastroesophageal reflux disease. World J Surg Oncol 2008; 6:74.
128. Yaghoobi M, Farrokhyar F, Yuan Y, Hunt RH. Is there an increased risk of GERD after Helicobacter pylori eradication? a meta-analysis. Am J Gastroenterol. 2010 May; 105(5):1007-13;quiz1006, 1014. Epub 2010Jan19.
129. Richter JE. The Many Manifestations of Gastroesophageal Reflux Disease: Presentation, Evaluation and Treatment Gastroenterol Clin N Am 2007,36:577–599
130. Fass R, Sifrim D. Management of heartburn not responding to proton pump inhibitors. Gut 2009;58;295-309
131. Uday C Ghoshal, Dipti Chourasia. Gastroesophageal Reflux Disease and Helicobacter pylori: What May Be the Relationship? J Neurogastroenterol Motil. 2010 July;16(3):243–250.
132. Metz DC, Kroser JA. Helicobacter pylori and gastroesophageal reflux disease. Gastroenterol Clin North Am 1999;28:971-985
133. Dent J. Is Helicobacter pylori relevant in the management of reflux disease ? Aliment Pharmacol Ther 2001:15(suppl1),16-21
134. Chourasia D, Achyut BR, Tripathi S, Mittal B, Mittal RD, Ghoshal UC. Genotypic and functional roles of IL-1B and IL-1RN on the risk of gastroesophageal reflux disease: the presence of IL-1B-511*T/IL-1RN*1 (T1) haplotype may protect against the disease. Am J Gastroenterol. 2009; 104:2704–2713.
135. Queiroz DM, Guerra JB, Rocha GA, et al. IL1B and IL1RN polymorphic genes and Helicobacter pylori cagA strains decrease the risk of reflux esophagitis. Gastroenterology. 2004; 127:73–79.
136. Wijetunge S, Ma Y, DeMeester S, Hagen J, DeMeester T, Chandrasoma P Association of adenocarcinomas of the distal esophagus, "gastroesophageal junction," and "gastric cardia" with gastric pathology. Am J Surg Pathol. 2010 Oct; 34(10):1521-7.
137. Chen TS, Chang FY. The prevalence and risk factors of reflux esophagitis among adult chinese population in Taiwan. J Clin Gastroenterol. 2007 Oct;41(9):819-22
138. Tefera S, Hatlebakk JG, Berstad AE, Berstad AEradication of Helicobacter pylori does not increase acid reflux in patients with mild to moderate reflux oesophagitis. Scand J Gastroenterol. 2002 Aug; 37(8):877-83.
139. Vaezi MF, Falk GW, Peek RM, Vicari JJ, Goldblum JR, Perez-Perez GI, Rice TW, Blaser MJ, Richter JE. CagA-positive strains of Helicobacter pylori may protect against Barrett's esophagus. Am J Gastroenterol. 2000 Sep; 95(9):2206-11.
140. McNamara D, Buckley M, Crotty P, Hall W, O'Sullivan M, O'Morain C. Carditis: all Helicobacter pylori or is there a role for gastro-oesophageal reflux? Scand J Gastroenterol. 2002 Jul; 37(7):772-7
141. Módena JL, Acrani GO, Micas AF, Castro M, Silveira WD, Módena JL, Oliveira RB, Brocchi M. Correlation between Helicobacter pylori infection, gastric diseases and life habits among patients treated at a university hospital in Southeast Brazil. Braz J Infect Dis. 2007 Feb; 11 (1):89-95.
142. Fass R, Sifrim D. Management of heartburn not responding to proton pump inhibitors. Gut 2009;58;295-309
143. Pichardo-Bahena R, Barredo-Prieto BA, Almeda-Valdés P, Chavez-Tapia NC, Méndez-Sánchez N. Esófago de Barrett, metaplasia gástrica y la presencia de Helicobacter pylori. Med Sur 2004;11(3):175-178
144. Zentilin P, Iiritano E, Vignale C, Bilardi C, Mele MR, Spaggiari P, Gambaro C, Dulbecco P, Tessieri L, Reglioni S, Mansi C, Mastracci L, Vigneri S, Fiocca R, Savarino V. Helicobacter pylori infection is not involved in the pathogenesis of either erosive or non-erosive gastro-oesophageal reflux disease. Aliment Pharmacol Ther. 2003 Apr; 17(8):1057-64
145. Anand O., Wani S., Sharma P. Gastroesophageal reflux disease and Barrett’s Esophagus. Endoscopy 2008;40:126-130
146. Guimarães EV, Guerra PV, Penna FJ. Management of gastroesophageal reflux disease and erosive esophagitis in pediatric patients: focus on delayed-release esomeprazole. Ther Clin Risk Manag. 2010; 6: 531–537.
147. Kamangar F, Chow WH, Abnet CC, Dawsey SM. Environmental causes of esophageal cancer. Gastroenterol Clin North Am 2009;38:27-57
148. Souza RC, Lima JH. Helicobacter pylori and gastroesophageal reflux disease: a review of this intriguing relationship. Dis Esophagus 2009;22:256-263
149. Wu JC, Lai AC, Wong SK, C han FK, Leung WK, Sung JJ. Dysfunction of oesophageal motility in Helicobacter pylori-infected patients with reflux oesophagitis. Aliment Pharmacol Ther. 2001 Dec; 15(12):1913-9.